Luis
Supply Chain at Apellis
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021
are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.
CLINICAL TRIALSWe challenge conventional thinking and always question if there's a better way.
Join UsPatricia
Quality Assurance at Apellis